Education
About Us
Working with TipRanks
Follow Us
Moleculin Biotech (DE:MOL)
:MOL
Total Valuation
Moleculin Biotech has a market cap or net worth of €9.95M. The enterprise value is €1.94M.
Market Cap€9.95M
Enterprise Value€1.94M
Share Statistics
Moleculin Biotech has 14.13M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding14.13M
Owened by Insiders0.68%
Owened by Instutions2.42%
Financial Efficiency
Moleculin Biotech’s return on equity (ROE) is -3.64 and return on invested capital (ROIC) is -227.97%.
Return on Equity (ROE)-363.99%
Return on Assets (ROA)-128.58%
Return on Invested Capital (ROIC)-227.97%
Return on Capital Employed (ROCE)-230.34%
Revenue Per Employee€0
Profits Per Employee-€1,280,176.471
Employee Count17
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Moleculin Biotech is -0.27. Moleculin Biotech’s PEG ratio is <0.01.
PE Ratio-0.27
PS Ratio0.00
PB Ratio0.98
Price to Fair Value0.98
Price to FCF-0.25
Price to Operating Cash Flow-0.25
PEG Ratio<0.01
Income Statement
In the last 12 months, Moleculin Biotech had revenue of €0.00 and earned -€21.76M in profits. Earnings per share was -€7.12.
Revenue€0.00
Gross Profit-€63.00K
Operating Income-€26.64M
Pretax Income-€21.76M
Net Income-€21.76M
EBITDA-26.52M
Earnings Per Share (EPS)-7.12
Cash Flow
In the last 12 months, operating cash flow was -€23.86M and capital expenditures -€13.00K, giving a free cash flow of -€23.88M billion.
Operating Cash Flow-€23.86M
Free Cash Flow-€23.88M
Free Cash Flow per Share-€1.69
Dividends & Yields
Moleculin Biotech pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-407.90%
Earnings Yield-371.82%
Stock Price Statistics
Beta-0.34
52-Week Price Change0.00%
50-Day Moving Average6.45
200-Day Moving Average6.45
Relative Strength Index (RSI)25.53
Average Volume (3m)0.00
Important Dates
Moleculin Biotech upcoming earnings date is May 8, 2025, TBA.
Last Earnings DateMar 24, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Moleculin Biotech as a current ratio of 0.97, with Debt / Equity ratio of 0.08
Current Ratio0.97
Quick Ratio0.97
Debt to Market Cap0.06
Net Debt to EBITDA0.14
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Moleculin Biotech has paid -€11.28K in taxes.
Income Tax-€11.28K
Effective Tax Rate0.00%
Enterprise Valuation
Moleculin Biotech EV to EBITDA ratio is -0.08, with an EV/FCF ratio of -0.09.
EV to Sales0.00
EV to EBITDA-0.08
EV to Free Cash Flow-0.09
EV to Operating Cash Flow-0.09
Balance Sheet
Moleculin Biotech has €4.28M in cash and marketable securities with €478.00K in debt, giving a net cash position of -€3.80M billion.
Cash & Marketable Securities€4.28M
Total Debt€478.00K
Net Cash-€3.80M
Net Cash Per Share-€0.27
Tangible Book Value Per Share-€1.50
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Moleculin Biotech is €5.27, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€5.27
Price Target Upside-18.30%
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast
EPS Growth Forecast